cannabis hyperemesis syndrome
Recently Published Documents


TOTAL DOCUMENTS

47
(FIVE YEARS 32)

H-INDEX

4
(FIVE YEARS 2)

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Hannah Lonsdale ◽  
Jerry M. Brown ◽  
Michael Wilsey

2021 ◽  
Author(s):  
Halis Kaan Akturk ◽  
Janet Snell-Bergeon ◽  
Gregory L Kinney ◽  
Anagha Champakanath ◽  
Andrew Monte ◽  
...  

<b>Objective</b> <p>To differentiate diabetic ketoacidosis (DKA) from hyperglycemic ketosis due to cannabis hyperemesis syndrome (HK-CHS) in adults with type 1 diabetes.</p> <p><b>Research Design and Methods</b></p> <p>Of 295 adults with type 1 diabetes who were seen with DKA related ICD-10 codes, 68 patients with 172 DKA events meeting the inclusion criteria were analyzed. Cannabis use was defined as positive urine test for cannabis. Linear mixed models were used to define HK-CHS (pH ≥7.4 with bicarbonate ≥ 15) and sensitivity and specificity were calculated using receiver operating characteristic (ROC).</p> <p><b>Results</b></p> <p>Cannabis users had significantly higher pH (7.42 ± 0.01 vs 7.09 ± 0.02) and bicarbonate (19.2 ± 0.61 vs 9.1 ± 0.71) (p<0.0001) compared to non-users. The area under the ROC for positive cannabis urine test predicting HK-CHS was 0.9892.</p> <p><b>Conclusions</b></p> <p>In patients who present with DKA and higher pH, especially pH ≥ 7.4, cannabis use should be considered in differential diagnosis.</p>


2021 ◽  
Author(s):  
Halis Kaan Akturk ◽  
Janet Snell-Bergeon ◽  
Gregory L Kinney ◽  
Anagha Champakanath ◽  
Andrew Monte ◽  
...  

<b>Objective</b> <p>To differentiate diabetic ketoacidosis (DKA) from hyperglycemic ketosis due to cannabis hyperemesis syndrome (HK-CHS) in adults with type 1 diabetes.</p> <p><b>Research Design and Methods</b></p> <p>Of 295 adults with type 1 diabetes who were seen with DKA related ICD-10 codes, 68 patients with 172 DKA events meeting the inclusion criteria were analyzed. Cannabis use was defined as positive urine test for cannabis. Linear mixed models were used to define HK-CHS (pH ≥7.4 with bicarbonate ≥ 15) and sensitivity and specificity were calculated using receiver operating characteristic (ROC).</p> <p><b>Results</b></p> <p>Cannabis users had significantly higher pH (7.42 ± 0.01 vs 7.09 ± 0.02) and bicarbonate (19.2 ± 0.61 vs 9.1 ± 0.71) (p<0.0001) compared to non-users. The area under the ROC for positive cannabis urine test predicting HK-CHS was 0.9892.</p> <p><b>Conclusions</b></p> <p>In patients who present with DKA and higher pH, especially pH ≥ 7.4, cannabis use should be considered in differential diagnosis.</p>


Diabetes Care ◽  
2021 ◽  
pp. dc211730
Author(s):  
Halis Kaan Akturk ◽  
Janet Snell-Bergeon ◽  
Gregory L Kinney ◽  
Anagha Champakanath ◽  
Andrew Monte ◽  
...  

Author(s):  
Helen Senderovich ◽  
Preet Patel ◽  
Briam Jimenez Lopez ◽  
Sarah Waicus

Introduction: Several forms of cannabinoids are currently being used to manage nausea and vomiting (N/V). Emerging cases of refractory N/V, associated with chronic cannabis use among adults and older patients have been reported named cannabis hyperemesis syndrome (CHS). CHS is a condition that leads to repeated and severe N/V in long-term users of cannabinoids. Objective: To outline current treatments for the management of CHS. Methods: A systematic review was conducted using PubMed, Ovid MEDLINE, Cochrane Central, EMBASE and Google Scholar. Databases were used to search for articles on CHS published from January 2009 to June 2021, yielding 225 results of which 17 were deemed relevant and underwent review by two separate reviewers. Results: The duration of cannabis administration ranged between six months to 11 years may precipitate symptoms of CHS. The Rome IV diagnostic criteria of CHS requires cannabinoid use and persistence if N/V symptoms for at least the past six months. Cannabis cessation is noted to be the most successful management, but other treatments also demonstrated symptom relief and included hot water hydrotherapy, topical capsaicin cream, haloperidol, droperidol, benzodiazepines, propranolol and aprepitant administration. Conclusion: Overall future research on CHS is needed which enhance knowledge translation, education and creates awareness of the medical community about the side effects of cannabinoids and propose the best treatment options.


2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Jonathan Cordova ◽  
Vincent Biank ◽  
Elizabeth Black ◽  
Jerrold Leikin

Author(s):  
Brian Lewis ◽  
Erin Leach ◽  
Larissa B. Fomum Mugri ◽  
Man Yee Keung ◽  
Lindsey Ouellette ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document